Unlocking the Potential of CC-92480: A Novel E3 Ligase Modulator for Relapsed and Refractory Multiple Myeloma

Discover the groundbreaking therapeutic potential of CC-92480, a novel protein degrader targeting multiple myeloma.

Get a Quote & Sample

Key Advantages

Targeted Protein Degradation

Experience the precision of CC-92480 protein degrader technology, which selectively targets and eliminates disease-causing proteins, offering a more refined therapeutic approach.

Enhanced Therapeutic Efficacy

Benefit from the Mezigdomide anti-myeloma activity, showcasing improved outcomes in relapsed and refractory multiple myeloma models through innovative E3 ligase modulation.

Mechanism of Action Clarity

Gain deep insights into the Cereblon E3 ligase modulator mechanism, understanding how CC-92480 triggers the degradation of Aiolos and Ikaros, leading to cell death.

Key Applications

Multiple Myeloma Research

Investigate CC-92480's role in advancing the understanding and treatment of relapsed and refractory multiple myeloma through precise protein degradation.

Drug Discovery & Development

Utilize CC-92480 as a critical pharmaceutical intermediate in the development of next-generation cancer therapies and targeted molecular glues.

Oncology Therapeutics

Explore the therapeutic implications of the Cereblon E3 ligase modulator mechanism in developing innovative treatments for various hematological malignancies.

Biochemical Research Tools

Employ CC-92480 as a high-purity biochemical tool to study ubiquitin-proteasome pathways and protein-protein interactions in cellular processes.